Skip to content
Screener

Arbutus Biopharma Corporation ABUS Accrued Research And Development

Accrued Research And Development at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$6.81M+56.1%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$5.74M+23.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$218K-62.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$98M+60.7%
Alumis Inc. logo
Alumis Inc.ALMS
$35.96M+3.6%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$86K—

Other financials

Income statement

See full
Revenue$1.0M-90.6%
Operating income-$6.0M-501%
Net income-$5.1M-304%
EPS (diluted)-$0.03-400%

Balance sheet

See full
Cash & equivalents$19.2M-48.8%
Total debt$514.0K-52.8%
Total equity$258.7M+212%
Total assets$274.0M+165%

Cash flow

See full
Operating cash flow-$6.0M+61.8%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$906.7M+41.2%
Enterprise value$888.04M+46.6%
P/E5.9×—
P/S5×-36.7×

Profitability

See full
Operating margin82%+44.9pp
Net margin84.2%+46.6pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity89.6%+65.3pp
Debt / equity0×0.0×
Current ratio81.4×+60.9×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept abus:AccruedResearchAndDevelopment.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 7:31 AM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q3 2026
Accession
0001447028-26-000045
Line itemJune 30, 2026December 31, 2025
Trade accounts payable$373$1,173
Research and development accruals448412
Professional fee accruals7351,075
Payroll accruals1,1342,159
Restructuring liabilities160640
Total accounts payable and accrued liabilities$2,850$5,459

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's accrued research and development?
Arbutus Biopharma Corporation (ABUS) reported accrued research and development of $448K in Q2 2026.
How has Arbutus Biopharma Corporation's accrued research and development changed year-over-year?
Arbutus Biopharma Corporation's accrued research and development decreased by 59.0% year-over-year, from $1.09M to $448K.
What is the long-term trend for Arbutus Biopharma Corporation's accrued research and development?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's accrued research and development has grown at a -24.3% compound annual growth rate (CAGR), from $1.65M to $412K.
What does accrued research and development mean?
Accrued Research And Development as reported by Arbutus Biopharma Corporation Common Stock.

Ask your AI about Arbutus Biopharma Corporation's accrued research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude